Wisp launches a weight care vertical to support women with hormonal imbalances
Wisp is a subsidiary of WELL Health
Women’s health company Wisp has announced it is moving into weight care with the launch of four weight care solutions - including GLP-1 medications - to support women struggling with hormonal conditions such as perimenopause, menopause, Polycystic Ovary Syndrome (PCOS), and endometriosis.
Wisp is the largest dedicated women’s telehealth provider in the US and currently serves over 1.2 million patients. It is a majority-owned subsidiary of WELL, a global digital healthcare company.
Monica Cepak, CEO of Wisp, said:
"Wisp is committed to providing sustainable support for women's weight loss journeys, addressing a critical yet overlooked aspect of women's health.”
"As the dialogue around obesity evolves, we recognise that underlying conditions — especially hormonal imbalances linked to perimenopause and menopause — remain under-researched, underdiagnosed, and undertreated. With these new offerings, we're proud to continue expanding access to comprehensive care, offering tailored solutions for every woman and every condition at every price point."
Four weight care solutions
Through the launch, Wisp introduces personalised, online consultations with access to four weight care solutions. One of the four solutions is Wisp’s first-ever over-the-counter weight care capsules, designed to promote women's metabolic health.
Wisp will now offer GLP-1 medications and supplements via pharmacy pickup or delivery, following an online health consultation with a licensed provider. The program also includes educational content and monthly check-ins to ensure effective support throughout the patient's journey.
The program includes: Semaglutide (FDA-approved Wegovy, Compounded Semaglutide, Metabolic Support & GLP-1 Boost Capsules (a supplement).
Hamed Shahbazi, Founder and CEO of WELL, said:
"The launch of Wisp's weight care vertical taps into the transformative potential of GLP-1 therapies."
"These treatments are reshaping healthcare by addressing weight management while enhancing metabolic health and alleviating hormonal challenges. For women experiencing conditions like PCOS, perimenopause, and menopause, GLP-1s open doors to improved health outcomes and a better quality of life. By integrating these therapies into Wisp's offerings, we are delivering personalized care at scale and positioning ourselves at the leading edge of women's healthcare innovation."
A boost for menopause
In tandem with this launch, Wisp strengthens its menopause solutions, addressing the healthcare gap for the over 2 million women experiencing menopause annually. New offerings include Estriol Face Cream and hormone replacement therapies such as Transdermal Estradiol Patches, Oral Micronized Progesterone Capsules, and Provera Tablets.
Wisp's upcoming plans also include new at-home diagnostics and treatment options in STI, fertility, menopause, and weight care categories.